Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell

Patent metadata

Field	Value
Publication number	US-9611465-B2
Application number	US-201514629452-A
Country	US
Kind code	B2
Filing date	Feb 23, 2015
Priority date	May 25, 2009
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.

First claim

The invention claimed is:

1. A method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, comprising:
contacting a test substance with a ubiquitin ligase complex comprising cereblon (CRBN);
measuring a ubiquitin ligase activity of the ubiquitin ligase complex;
selecting the test substance that increased the ubiquitin ligase activity of the ubiquitin ligase complex as compared with a ubiquitin ligase activity of the ubiquitin ligase complex without contacting the test substance; and
identifying the substance as a potential therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex.

2. The method of claim 1 , wherein the disease of cerebral cortex is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob disease, Huntington's disease, progressive supranuclear palsy, and corticobasal degeneration.

3. The method of claim 1 , wherein the ubiquitin ligase complex comprising CRBN is from a neural stem cell or a neural progenitor cell of a subject.

Assignees

• Celgene Corp

Inventors

• Handa Hiroshi
• Ando Hideki
• Itoh Takumi
• Hotta Kentaro

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12Y603/02019

  Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K38/45

  Transferases (2) · CPC title

• C12N9/93

  Ligases (6) · CPC title